Fondaparinux verses enoxaparin for the prevention of venous thromboembelism


Autoria(s): Doggrell, Sheila A.
Contribuinte(s)

Michelle Dror

Data(s)

01/04/2002

Resumo

Venous thromboembolism is a frequent, life-threatening, postoperative complication of hip-fracture and total-knee-replacement surgery. Fondaparinux is a synthetic polysaccharide that selectively binds to antithrombin, the primary endogenous regulator of blood coagulation. Low molecular weight heparins, such as enoxaparin, are less specific inhibitors of coagulation. In patients undergoing hip-fracture surgery, fondaparinux is more effective than once-daily enoxaparin as prophylaxis for venous thromboembolism. Fondaparinux (25 mg/day s.c.) was also more effective than enoxaparin (30 mg s.c. b.i.d.) as prophylaxis for venous thromboembolism in elective knee surgery. These differences may be explained by the fact that there is less prophylaxis cover with enoxaparin, as it has a much shorter duration of action than fondaparinux. Thus, with the present dosing regimens, fondaparinux is probably preferable to enoxaparin for the prevention of venous thromboembolism.

Identificador

http://espace.library.uq.edu.au/view/UQ:64195

Idioma(s)

eng

Publicador

Ashley Publications Ltd.

Palavras-Chave #CX #320503 Clinical Pharmacology and Therapeutics #730106 Cardiovascular system and diseases
Tipo

Journal Article